Cancer screening resident survival guide: Difference between revisions
Jump to navigation
Jump to search
TayyabaAli (talk | contribs) |
TayyabaAli (talk | contribs) |
||
Line 50: | Line 50: | ||
===Colorectal Cancer=== | ===Colorectal Cancer=== | ||
*[[Colorectal cancer]] screening starts among asymptomatic adults at the age of 50 with no family history of [[adenoma]] or [[colorectal cancer]]. It is preferably done via [[colonoscopy]]<ref name="pmid27304597">{{cite journal| author=US Preventive Services Task Force. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW | display-authors=etal| title=Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. | journal=JAMA | year= 2016 | volume= 315 | issue= 23 | pages= 2564-2575 | pmid=27304597 | doi=10.1001/jama.2016.5989 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27304597 }} </ref> | *[[Colorectal cancer]] screening starts among asymptomatic adults at the age of 50 with no family history of [[adenoma]] or [[colorectal cancer]] (CRC). It is preferably done via [[colonoscopy]]<ref name="pmid27304597">{{cite journal| author=US Preventive Services Task Force. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW | display-authors=etal| title=Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. | journal=JAMA | year= 2016 | volume= 315 | issue= 23 | pages= 2564-2575 | pmid=27304597 | doi=10.1001/jama.2016.5989 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27304597 }} </ref> | ||
*According to the GLOBOCAN 2018 estimates of cancer incidence, mortality, and prevalence, [[Colon cancer]] is the fourth commonly occurring [[cancer]] (6.1% for incidence). It is the third cause of death in cancer patients (9.2% of total cancer deaths).<ref name="pmid30207593">{{cite journal| author=Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A| title=Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | journal=CA Cancer J Clin | year= 2018 | volume= 68 | issue= 6 | pages= 394-424 | pmid=30207593 | doi=10.3322/caac.21492 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30207593 }} </ref> | *According to the GLOBOCAN 2018 estimates of cancer incidence, mortality, and prevalence, [[Colon cancer]] is the fourth commonly occurring [[cancer]] (6.1% for incidence). It is the third cause of death in cancer patients (9.2% of total cancer deaths).<ref name="pmid30207593">{{cite journal| author=Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A| title=Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | journal=CA Cancer J Clin | year= 2018 | volume= 68 | issue= 6 | pages= 394-424 | pmid=30207593 | doi=10.3322/caac.21492 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=30207593 }} </ref> | ||
{| class="wikitable" | |||
| colspan="3" align="center" style="background: #4479BA; color: #FFFFFF " |'''Recommendations for Colorectal cancer screening:'''<ref name="urlRecommendation: Cervical Cancer: Screening | United States Preventive Services Taskforce">{{cite web |url=https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening |title=Recommendation: Cervical Cancer: Screening | United States Preventive Services Taskforce |format= |work= |accessdate=}}</ref> | |||
|- | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Population}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Screening recommendations}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | '''Age 50 asymptomatic with no history of CRC or adenoma''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
'''Direct Visualization Tests''' | |||
*Colonoscopy (every 10 years) | |||
*Flexible sigmoidoscopy (every 5 years) | |||
*Flexible sigmoidoscopy (every 10 years) with fecal immunochemical test (every year) | |||
*CT colonography (every 5 years) | |||
'''Stool-Based Tests''' | |||
*Guaiac-based fecal occult blood test (gFOBT) (every year) | |||
*Fecal immunochemical test (FIT) (every year) | |||
*Multitargeted stool DNA test (FIT-DNA) (every 1 year or 3 years) | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | '''Age less than 21''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*screening not recommended | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" |'''Age 21-29''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*[[Pap test]] [[(cytology)]] every 3 years | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | '''Age 30-65''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
*[[Cytology]] every 3 years or | |||
*[[Cytology]] and [[HPV testing]] (co-testing) every 5 years | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | '''Age 65 or greater than 65''' | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
'''Discontinue cervical cancer screening''' | |||
*Age 65 with no risk for [[cervical cancer]] (e.g., immunosuppression, high risk sexual activity, tobacco use, [[diethylstilbestrol]] exposure) or [[hysterectomy]] and | |||
*No history of [[cervical intraepithelial neoplasia]] grade 2 or higher and | |||
* 3 consecutive negative [[pap smear|pap tests]] or | |||
*2 consecutive negative co-testing results | |||
|} | |||
* To view the detailed information on [[colorectal cancer screening]] [[Colorectal cancer screening|click here]]. | * To view the detailed information on [[colorectal cancer screening]] [[Colorectal cancer screening|click here]]. | ||
Revision as of 14:44, 4 August 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Tayyaba Ali, M.D.[2]
Overview
This section provides a short and straight to the point overview of the disease or symptom. The first sentence of the overview must contain the name of the disease.
Common Cancers
Breast Cancer
- Breast cancer screening starts at the age of 50 via a mammogram twice a year and discontinues at the age of 74.[1]
- According to the GLOBOCAN 2018 estimates of cancer incidence, mortality, and prevalence, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death among females (11.6% of total cancer deaths).[2]
- To view the detailed information on breast cancer screening click here.
Cervical Cancer
- Cervical cancer screening starts at the age of 21 regardless of the onset of sexual activity via Papanicolaou test (Cervical cytology).[3]
- According to the GLOBOCAN 2018 estimates of cancer incidence, mortality, and prevalence, cervical cancer ranks fourth for both incidence and mortality among females.[2]
Recommendations for Cervical cancer screening:[3] | ||
Population | Screening recommendations | |
---|---|---|
Immunocompromised |
| |
Age less than 21 |
| |
Age 21-29 |
| |
Age 30-65 |
| |
Age 65 or greater than 65 |
Discontinue cervical cancer screening
|
To view the detailed information on cervical cancer screening click here.
Colorectal Cancer
- Colorectal cancer screening starts among asymptomatic adults at the age of 50 with no family history of adenoma or colorectal cancer (CRC). It is preferably done via colonoscopy[4]
- According to the GLOBOCAN 2018 estimates of cancer incidence, mortality, and prevalence, Colon cancer is the fourth commonly occurring cancer (6.1% for incidence). It is the third cause of death in cancer patients (9.2% of total cancer deaths).[2]
Recommendations for Colorectal cancer screening:[3] | ||
Population | Screening recommendations | |
---|---|---|
Age 50 asymptomatic with no history of CRC or adenoma |
Direct Visualization Tests
Stool-Based Tests
| |
Age less than 21 |
| |
Age 21-29 |
| |
Age 30-65 |
| |
Age 65 or greater than 65 |
Discontinue cervical cancer screening
|
- To view the detailed information on colorectal cancer screening click here.
Endometrial Cancer
Esophageal Cancer
Lung Cancer
- Lung cancer screening starts among asymptomatic adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit smoking within the past 15 years.[5]
- According to the GLOBOCAN 2018 estimates of cancer incidence, mortality, and prevalence, Lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death in both males and females (18.4% of the total cancer deaths).[2]
Recommendations for lung cancer screening:[5] | ||
Recommended test | ||
Recommended Interval |
| |
Age for screening |
| |
Eligibility for screening based on smoking history |
| |
Discontinuation of screening |
|
- To view the detailed information on Lung cancer screening click here.
Ovarian cancer
- There are no recommendations for screening ovarian cancer in asymptomatic women although the better outcome is associated with early diagnosis.[6]
- To view the detailed information on ovarian cancer screening click here.
Prostate Cancer
- According to the GLOBOCAN 2018 estimates of cancer incidence, mortality, and prevalence, Prostate cancer is the second cause of cancer death in males (7.1% of the total cancer deaths).[2]
References
- ↑ "Recommendation: Breast Cancer: Screening | United States Preventive Services Taskforce".
- ↑ 2.0 2.1 2.2 2.3 2.4 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018). "Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries". CA Cancer J Clin. 68 (6): 394–424. doi:10.3322/caac.21492. PMID 30207593.
- ↑ 3.0 3.1 3.2 "Recommendation: Cervical Cancer: Screening | United States Preventive Services Taskforce".
- ↑ US Preventive Services Task Force. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW; et al. (2016). "Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement". JAMA. 315 (23): 2564–2575. doi:10.1001/jama.2016.5989. PMID 27304597.
- ↑ 5.0 5.1 "Recommendation: Lung Cancer: Screening | United States Preventive Services Taskforce". Retrieved 8/3/2020. Check date values in:
|accessdate=
(help) - ↑ "Recommendation: Ovarian Cancer: Screening | United States Preventive Services Taskforce".